Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer

About this update from Corbus Pharmaceuticals Holdings, Inc.

NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer. “We’re thrilled to welcome Dr. Nicacio to Corbus, particularly as we approach initiation of our TEMPO-1 registrational study of CRB-701 in 2L oropharyngeal squamous cell carcinoma (OPSCC) this summer,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “Dr. Nicacio brings a highly relevant background in solid tumor drug development and commercialization, including his pivotal role advancing the antibody drug conjugate (ADC) TIVDAK® to market for metastatic cervical cancer. His extensive experience in ADCs as well as the HPV-driven oncology space is well matched to our strategic priorities and our continued advancement of CRB-701 for OPSCC and cervical cancer.” “I’m delighted to join Corbus at a time of notable evolution for the Company. Corbus is advancing toward multiple near-term milestones in quick succession, including CRB-701’s expected imminent entry into late-stage clinical development in 2L OPSCC, a planned readout of the CANYON-1 obesity study of CRB-913 in late summer, and an anticipated data readout of CRB-701 in 1L OPSCC in early 2027,” said Dr. Nicacio. “I’m excited to work with Yuval and the entire team as we simultaneously advance both of these novel drug candidates to address the significant unmet needs of three distinct patient populations.” Dr. Nicacio’s career spans over 20 years in the pharmaceutical industry. Prior to joining Corbus, he was the Chief Medical Officer at Protara Therapeutics, a clinical-stage company developing therapies for the treatment of cancer and rare diseases. Prior to Protara, Dr. Nicacio served as Senior Vice President, Head of Clinical Development and Global Medical Affairs at Stemline Therapeutics, a subsidiary of the Menarini Group, where he was responsible for establishing and executing global strategies for solid tumor development. From 2017 to 2023, he held roles of increasing responsibility at Seagen (acquired by Pfizer in December 2023), most recently as Vice President of Clinical Development, overseeing programs across a range of cancers, including bladder, breast, gynecologic, lu...

View stock analysis, news, and events for Corbus Pharmaceuticals Holdings, Inc.